Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Inhibition of autoimmune encephalomyelitis by a tetracycline.
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis.
Plasma chemerin levels in patients with multiple sclerosis.
Clinical Assessment of Orofacial Manifestations in 500 Patients With Multiple Sclerosis.
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Scrub typhus with longitudinally extensive transverse myelitis.
Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils.
Potential role of OPG/RANKL system and FokI genotypes in pathogenesis and clinical manifestations in multiple sclerosis.
FDA Approves First Drug for Lou Gehrig's Disease
Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life.
Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis.
Switching to Gilenya® (fingolimod) from a standard interferon offers sustained freedom from disease activity for people with relapsing remitting multiple sclerosis
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
Simvastatin in acute optic neuritis.
CD44 is required for the migration of transplanted oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal cord.
B cells and antibodies in multiple sclerosis pathogenesis and therapy.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.
Medication withdrawal in relapsing-remitting multiple sclerosis: why not?
Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets.
Effects of sleep and wake on oligodendrocytes and their precursors.
Fine-tuning the central nervous system: microglial modelling of cells and synapses.

Pages